---
title: "Edgewise Therapeutics, Inc. (EWTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EWTX.US.md"
symbol: "EWTX.US"
name: "Edgewise Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-06-10T12:59:23.215Z"
locales:
  - [en](https://longbridge.com/en/quote/EWTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EWTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EWTX.US.md)
---

# Edgewise Therapeutics, Inc. (EWTX.US)

## Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [edgewisetx.com](https://edgewisetx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -20.82 | 207 | - | - | - |
| PB | 7.43 | 169 | 6.30 | 4.46 | 2.82 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-05T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 58% |
| Overweight | 3 | 25% |
| Hold | 2 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 34.06 |
| Highest Target | 66.00 |
| Lowest Target | 20.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/EWTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/EWTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/EWTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/EWTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**